Pfizer Inc. (NYSE: PFE) shares saw a modest uptick on Friday, gaining 0.36% to trade around $26.27, following an upgrade from RBC Capital. The stock had already risen 2.23% on Thursday, outperforming the broader healthcare sector. The move comes after RBC Capital analyst Trung Huynh raised his rating on the pharmaceutical giant to Sector Perform from Underperform, while maintaining a $25 price target. Huynh noted that the risk-reward profile has become more balanced after the stock's decline from its 2026 highs.
RBC's Neutral Stance
RBC Capital's upgrade reflects a more neutral outlook on Pfizer, with the analyst stating that the shares are now closer to the firm's 9-times one-year forward price-to-earnings target. The forward P/E ratio measures a stock's price relative to expected earnings, and a lower multiple can signal value. Despite the upgrade, RBC's price target of $25 remains below the current trading price, suggesting limited upside in the near term.
Key Catalysts Ahead
Investors are now turning their attention to Pfizer's 2026 oncology trial readouts, which are widely seen as critical catalysts for the stock. The company is set to release data for mevrometostat in first- or second-line metastatic castration-resistant prostate cancer, as well as sigvotatug vedotin in second-line-plus non-squamous metastatic non-small cell lung cancer. RBC highlighted these mid-2026 and second-half 2026 readouts as important for investor sentiment. Positive trial results could significantly boost Pfizer's pipeline prospects and stock performance.
Drug-Pricing Concerns Persist
European drug-pricing pressure remains a significant risk for Pfizer. Recent reports indicated that CEO Albert Bourla discussed potential drug price legislation with German Chancellor Friedrich Merz, which could impact the company's projects in Germany. Lower reimbursed drug prices in Europe could reduce future revenue, adding uncertainty for investors. This policy risk is a key factor that could weigh on the stock's valuation.
Financial Performance
Pfizer's first-quarter 2026 revenue came in at $14.45 billion, a 5% increase year-over-year. The company maintained its full-year revenue guidance of $59.5 billion to $62.5 billion and adjusted diluted EPS target of $2.80 to $3.00. Revenue from new and acquired products grew 22% operationally, though sales of Comirnaty and Paxlovid continued to decline. The stock's dividend yield of approximately 6.6% provides some support for income-focused investors.
Market Sentiment
Analysts tracked by MarketBeat rate Pfizer as a Hold, with an average 12-month price target of $28.82, implying about 10% upside from current levels. However, RBC's $25 target is below the current price, which may appeal to yield-seeking investors willing to accept pipeline and policy risks. For those seeking quicker gains, the stock may be less attractive unless upcoming oncology results or guidance signal a stronger post-COVID profit recovery.
